Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III studyVito Lorusso, Giuseppe Colucci, Francesco Giotta et al.|International Journal of Oncology|2014Cited by 26
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Giammarco Surico, Vincenzo Emanuele Chiurì et al.|Breast Cancer Research and Treatment|2017Cited by 12
Abstract P4-13-15: Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real world population of hormone receptor positive advanced breast cancer: A multicenter Italian experienceR. Forcignanò, Mariangela Ciccarese, Luciana Petrucelli et al.|Cancer Research|2016Cited by 0
A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).Vito Lorusso, Giuseppe Colucci, Francesco Giotta et al.|Journal of Clinical Oncology|2011Cited by 0